Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.66 |
| ▸ | HTR2A | P28223 | 5/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4699560 | 0.99 | HTR6 (0.65) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4698757 | 0.89 | HTR6 (0.72) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4697886 | 0.88 | HTR6 (0.71) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4700085 | 0.80 | TSHR (0.51) | ALDH1A1KDM4EHTTPKMMEN1 | |
| SCHEMBL4702216 | 0.80 | HTR6 (0.59) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Intepirdine SCHEMBL1683964 | 0.80 | HTR6 (1.00) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Intepirdine SCHEMBL29355057 | 0.80 | HTR6 (1.00) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4699246 | 0.80 | TGM2 (0.46) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4698200 | 0.79 | HTR6 (0.58) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4702019 | 0.79 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660483-B1 | 8-(1-PIPERAZINYL)-QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-12-24 | — | — | EP | claimed |
| US-20080275040-A1 | 8-(1-Piperazinyl)-Quinoline Derivatives and Their Use in the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | claimed |
| EP-1660483-A1 | 8-(1-PIPERAZINYL)-QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021530-A1 | 8- (1-PIPERAZINYL)- QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | WO | claimed |
| EP-1660483-B1 | 8-(1-PIPERAZINYL)-QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-20080275040-A1 | 8-(1-Piperazinyl)-Quinoline Derivatives and Their Use in the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275040-A1 | 8-(1-Piperazinyl)-Quinoline Derivatives and Their Use in the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275040-A1 | 8-(1-Piperazinyl)-Quinoline Derivatives and Their Use in the Treatment of Cns Disorders | PMP22, AQP4, SLC18A2 | HTR6 139/4885HTR2A 82/4885HTR1A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.